We studied single nucleotide polymorphisms (SNPs) and haplotypes in the urotensin-II (UTS2) and urotensin-II receptor gene (UTS2R) in Hong Kong Chinese (224 hypertensive and 306 normotensive unrelated subjects) and their relation to hypertension and the metabolic syndrome. For UTS2, the GGT haplotype (-605G, 143G, 3836T) was associated with higher plasma level of U-II and insulin, and higher homeostasis model assessment of insulin resistance index and β-cell function. For UTS2R, the AC haplotype (-11640A, -8515C) was associated with higher 2-hour plasma glucose after a 75-g oral glucose load. Therefore, U-II and its receptor may play a role in insulin resistance.
Introduction
U-II is the most potent vasoconstrictor known and is more potent than endothelin-1 (ET-1) [3] . Human U-II is an 11 amino acid cyclic peptide and is derived from a precursor molecule, prepro-U-II [22, 23] . The gene encoding the peptide, UTS2, is located at 1p36 and contains 5 exons. U-II acts through a G-protein-coupled receptor, the UT receptor [3] . The gene encoding the receptor, UTS2R, is located at 17q25.3 and is intronless [24] .
U-II circulates in human plasma and its plasma level is elevated in renal failure [41] , congestive heart failure [16, 21, 27, 28] , portal hypertension caused by liver cirrhosis [14] and diabetes mellitus [39] . We previously reported that plasma U-II level is raised in hypertensive patients compared to normotensive controls and is directly related to the systolic blood pressure [8] . On the other hand, the elevation in plasma U-II level in diabetic patients is independent of the level of blood glucose [39] . U-II inhibits insulin secretion in the rat pancreas [31] . In Type 2 diabetic patients, plasma and urinary U-II level is higher in those with renal dysfunction than those with normal renal function [40] .
A single nucleotide polymorphism (SNP) in UTS2, 143G>A (rs228648), is associated with susceptibility to type 2 diabetes in Han Chinese [36, 48] . Another SNP, 3836C>T (rs2890565) is associated with increased insulin resistance and susceptibility to type 2 3 diabetes in Japanese [37, 45] . However, in previous studies of SNPs in UTS2 [36, 37, 45, 48] there are no reports of SNPs in the promoter and haplotype analysis, and the influence of these SNPs on plasma U-II level has not been investigated. For the UT receptor, there is only one report of SNP study in Japanese population in which no SNP can be found in the coding region and the two SNPs in promoter region, -7836G>A and -7814C>T did not show any association with type 2 diabetes mellitus and related clinical parameter. Therefore, we hypothesized that U-II may play a role in the development of hypertension and metabolic syndrome, which is a cluster of metabolic abnormalities, associated with central (abdominal) obesity, raised fasting plasma glucose, raised blood pressure, raised triglycerides and reduced HDL cholesterol [2] . In this study, we sequenced the UTS2 promoter for novel SNPs, and investigated the association of haplotypes and SNPs in the UTS2 gene with hypertension and clinical parameters important in metabolic syndrome, such as insulin resistance, plasma glucose, plasma insulin, lipid profile and blood pressure, etc. We also investigated the association of two known SNPs in the UTSR2 gene promoter, -11640G>A (rs7502620) and -8515T>C (rs7211435) which has been documented in the HapMap database, with the clinical parameters.
Subjects and Methods

4
Subjects
The study protocol had been approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. We studied 224 hypertensive patients and 306 normotensive controls with their informed consent. The subjects were all unrelated Hong Kong Chinese. Hypertensive subjects were recruited from the Hypertension Clinic of a teaching hospital. Hypertension was defined as systolic blood pressure ≥140mmHg, or a diastolic blood pressure ≥90mmHg on at least 3 separate occasions.
Patients on treatment who were previously diagnosed as hypertensive by the above criteria were also eligible. Patients with secondary hypertension (e.g. renal artery stenosis, coarctation, glomerulonephritis, pyelonephritis, phaeochromocytoma, Cushing's syndrome, Conn's syndrome) were excluded. Normotensive controls were recruited from a cohort of subjects previously randomly recruited from the general population [9, 15] .
Physical examination (including measurement of height, weight, body fat, waist and hip circumference), urine analysis and ECG were performed and a full medical history (including past medical history, drug history, family history, smoking status, alcohol intake and exercise habit) was obtained. Bioelectrical impedance was measured as an estimate of percentage body fat (Tanita TBF-531, Tanita Corporation, Tokyo, Japan). Lipid profile, fasting glucose, insulin and 2-hour glucose after a 75-g oral glucose load were measured. Insulin resistance 5 was assessed with the homeostasis model assessment of insulin resistance index (HOMA-IR), which is the product of the fasting plasma insulin (FPI) (mIU/L) and fasting plasma glucose (FPG) (mmol/L) divided by 22.5 [18] . Pancreatic β-cell function, estimated as HOMA-β%, is given by (20xFPI)/(FPG-3.5).
Subjects were studied in the morning after overnight fasting. The blood pressure of each patient was measured using a mercury sphygmomanometer by a trained nurse manually after the subject had been sitting and resting for at least 5 minutes. Blood pressure was measured three times at 5 minute intervals. The first blood pressure measurement was to familiarise the patient with the procedure and the sensation of the inflated cuff. The 2 subsequent systolic and phase V diastolic blood pressure readings were recorded to the nearest 2mmHg. The mean of the 2 readings was used in data analysis.
After sitting or resting for at least 5 minutes, 20ml venous blood was taken from a forearm vein for a full blood count (haemoglobin, haematocrit, white blood count, differential white count and platelet count), renal and liver function tests (sodium, potassium, urea, creatinine, glucose, total bilirubin, total protein, albumin, ALT and alkaline phosphatase), plasma insulin and lipid profile. In 29 hypertensive subjects and 54 control subjects, 10 ml venous blood was placed in a pre-chilled EDTA bottle and placed on ice immediately. In an adjacent room, 6 the blood was immediately centrifuged at 4°C to obtain the buffy coat and the plasma was frozen at -70°C until the time of assay. Plasma U-II was measured by radioimmunoassay as described previously [8].
Genomic DNA Amplification and SNP identification
Genomic DNA was extracted from the buffy coat using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Candidate SNPs were selected from the dbSNP database and their locations are shown in Figure 1 . Genomic sequence was obtained from GenBank (accession numbers NT021937 and NT010663). To sequence a 1,600-bp UTS2 promoter region, three primer sets were designed. PCR reactions were performed in 22-27 subjects using primers, U2P1 (5'-AGT GAC GCA GAG CAT AAG ATG A-3') and U2P2 (5'-CAC CAC ACC TGG TTA ATT GTT G-3') to amplify a 1019bp from +120 to -899, U2P3 (5'-CTG GGC AAC ATA GAG AAA CAC-3') and U2P4 (5'-CCT CCT GTC TCA ATT TTT TTC-3') to amplify a 627bp segment from -525 to -1151, and U2P5 (5'-AGA CAA GAC ACA AAT CAC ACA G-3') and U2P6 (5'-AGT TTT GCT CTT GCC ACC C-3') to amplify a 534bp segment from -1109 to -1642. The SNPs in the UTS2 promoter region were identified by direct sequencing using ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, USA). 7 
Genotyping
High-throughput genotyping of the SNPs in UTS2 (except -605G>A and -788C>T) and UTS2R were performed using the Sequenom MassARRAY system (Sequenom, San Diego, The digested products were analyzed by gel electrophoresis in 10% polyacrylamide gels.
Statistical analysis
Data were analysed using a statistical software programme (SPSS for Windows, ver. 11.0, SPSS Inc., Chicago, USA [5] . Haplotypes were predicted using the programme PHASE (ver. 2.1.1), which implements a Bayesian method for estimating haplotypes from population genotype data [7, 33, 34] . For haplotype analysis, subjects who carried a particular haplotype with a probability ≥0.95 were also included. Analysis of covariance (ANCOVA) was used for comparing the fasting plasma insulin, HOMA-IR, HOMA-β%, plasma U-II level and 2-hour plasma glucose of groups with different haplotypes, with age, sex, BMI and HOMA-IR as covariates where indicated. A 2-tailed p-value less than 0.05 was considered statistically significant.
Results
Baseline characteristics
We studied 224 hypertensive subjects and 306 normotensive controls. Their baseline characteristics are shown in Table 1 . There were as expected, significant differences in 9 blood pressure, weight, BMI, percentage body fat, plasma cholesterol level, fasting plasma glucose, fasting plasma insulin, HOMA-IR, HOMA-β%, plasma U-II level and the prevalence of diabetes mellitus and metabolic syndrome according to the NCEP ATP III guidelines [20] . Genotyping of the two SNPs -11640G>A and -8515T>C in UTS2R were performed in only 174 normotensive controls and 114 hypertensive subjects. 
Plasma U-II level and HOMA-IR
Identification of SNPs in UTS2 promoter by direct sequencing
Five SNPs were identified in the promoter region of UTS2 by direct sequencing. A novel (C>T) SNP was found at position -788 which has not been reported before. The other SNPs (-18C>T, -605G>A, -1263C>T and -1477C>T) have been reported in the dbSNP database previously and showed heterozygosity in our population. However, the minor allele frequencies of -18C>T and -1477C>T were less than 5% and therefore not further analysed.
Two SNPs (-660C>T and -789G>A) previously identified in African Americans as described 10 in the dbSNP database were homozygous in our sample.
SNP genotyping
The -605G>A and -788C>T variants were genotyped by FokI-RFLP (Figure 3a) and (Figure 3b ) respectively, while other SNPs in UTS2 (-1263C>T, 143G>A and 3836C>T) and UTS2R (-11640G>A and -8515T>C) were genotyped using the Sequenom.
MwoI-RFLP
The results are shown in Table 2 . For each SNP, the observed genotype frequencies showed no significant deviation from Hardy-Weinberg equilibrium.
Linkage disequilibrium
In this study, r 2 was used to measure linkage disequilibrium as it is independent of allele frequency and appropriate for modest sample sizes [13, 29] . The average r 2 value across the UTS2 gene was 0.18. The SNPs, -605G>A and 143G>A are in almost complete linkage disequilibrium (r 2 = 0.99). For UTS2R, the 2 SNPs, -11640G>A and -8515T>C are also in almost complete linkage disequilibrium (r 2 = 0.99).
Single variant analysis of UTS2
Plasma U-II level was related to 3836C>T (Table 3 , p=0.006 after adjusting for sex, age and BMI), especially among the normotensive subjects (p=0.002 and after adjustment, p=0.002).
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Plasma U-II level was not significantly related to -1263C>T, -788C>T, -605G>A or 143G>A (Table 3) .
The 3 SNPs, -605G>A, 143G>A and 3836C>T were significantly associated with HOMA-β% (Table 4 ). 3836C>T was also significantly associated with higher fasting plasma insulin and HOMA-IR. The associations remained significant after adjusting for sex, age and BMI (p=0.024, 0.038 and 0.040 for plasma insulin, HOMA-IR and HOMA-β% respectively). However, none of the SNPs studied was associated with hypertension (Table   2 ), waist circumference, plasma triglyceride, plasma cholesterol, plasma HDL cholesterol, fasting plasma glucose or blood pressure (p>0.05).
Haplotype analysis of UTS2
The most common five-locus haplotypes, comprising the five nucleotide variants at positions (Table 4 ). The association remained significant after adjusting for age, sex and BMI (p=0.029, 0.045 and 0.049 respectively). Moreover, the fasting plasma insulin, HOMA-IR and HOMA-β% increased with number of GGT haplotype (p=0.017, 0.032 and 0.021). Among non-diabetic normotensive subjects, the GGT haplotype was only associated with higher fasting plasma insulin and HOMA-IR, but not HOMA-β% (p=0.038, 0.026 and 0.274 respectively and after adjusting for age, sex and BMI, p=0.037, 0.024 and 0.309 respectively). However, none of the haplotypes studied was associated with hypertension, waist circumference, plasma triglyceride, plasma cholesterol, plasma HDL cholesterol, fasting plasma glucose or blood pressure (p>0.05).
Carriers of GGT haplotypes had higher plasma U-II level (Table 3 , p=0.016 after adjusting for sex, age and BMI), especially among the normotensive subjects (p=0.006 and after adjustment, p=0.007).
Single variant and haplotype analysis of UTS2R
Both the two SNPs, -11640G>A and -8515T>C were significantly associated with higher 2-hour plasma glucose after a 75-g oral glucose load ( Table 5 ). The associations remained significant after adjusting for sex, age and BMI (p=0.024 for both -11640G>A and 13 -8515T>C). The most common 2-locus haplotypes, comprising nucleotide variants at positions -11640 and -8515, and their frequencies were GT (0.70) and AC (0.30). The AC haplotype showed similar results as the corresponding single variant ( Table 5 ). The association of AC haplotype with 2-hour plasma glucose remained significant after adjusting for.sex, age, BMI and HOMA-IR (p=0.020) and is more significant among the non-diabetic normotensive subjects (p=0.001 and after adjustment, p=0.016). However, none of the SNPs and haplotypes studied was associated with hypertension, waist circumference, plasma triglyceride, plasma HDL cholesterol, blood pressure, fasting plasma glucose, fasting plasma insulin, HOMA-IR and HOMA-β%, (p>0.05).
Discussion
The most important findings of this study were the associations of haplotypes and SNPs in the UTS2 gene with plasma U-II level, insulin resistance and pancreatic β-cell function and that in UTS2R gene with 2-hour plasma glucose. We previously reported that plasma U-II level is raised in hypertensive patients compared to normotensive controls and is directly related to the systolic blood pressure [8] . Hypertension and insulin resistance are commonly found together in overweight persons as components of the metabolic syndrome [20, 26] . In our local population, overweight and insulin resistance are important determinants of blood pressure [38] . Plasma insulin level and blood pressure are correlated in untreated patients 14 with essential hypertension but not in those with secondary hypertension [32] . Insulin resistance and hyperinsulinemia can raise the blood pressure by a variety of mechanisms including activation of the renin-angiotensin-aldosterone and the sympathetic nervous systems, sodium retention, volume expansion, renal damage, atherosclerosis and oxidative stress [12] . Impaired insulin signalling in the insulin-resistant state contributes to vasoconstriction.
Previously, 143G>A (T21M) polymorphism was found to be associated with diabetes mellitus in northern Chinese [36, 48] . In Japanese subjects, 3836C>T (S89N) but not 143G>A, was reported to be significantly associated with type 2 diabetes, increased plasma insulin and higher HOMA-IR [37, 45] . Our results on 3836C>T is consistent with that of Japanese study, showing the association of this polymorphism with insulin resistance.
The region 1p36 in human chromosome 1 contains the susceptible locus for type 2 diabetes in Chinese and Japanese [11, 19] . The exact disease-containing gene remains to be identified.
The UTS2 gene is at 1p36, raising the possibility that it may be one of the genes causing the metabolic syndrome. Local expressions of both U-II and UT receptor have been demonstrated in human pancreas [3, 10, 35] . In perfused rat pancreas, glucose-induced insulin release can be inhibited by infusion of 10nM and 100nM U-II while arginine-induced 15 insulin release can be inhibited by infusion of 100nM [31] . This inhibition is not due to the vasoconstriction action of U-II but its activation of UT receptors in pancreatic β cells and does not affect basal insulin release [30] . In this study, the associations of SNPs and haplotype in UT receptor with 2-hour plasma glucose level suggest a role of UT receptor in the development of impaired glucose tolerance which is a precursor to diabetes mellitus.
The AC haplotype may increase the receptor sensitivity, density or expression, thus enhancing the inhibitory effect of U-II on insulin secretion in response to glucose load and resulting in a higher 2-hour plasma glucose level. This new finding further supports a role of U-II and its receptor in the regulation of insulin secretion and glucose metabolism.
However, early type 2 diabetes is characterised by hyperinsulinaemia rather than impairment in insulin production. Interestingly, we found that the U-II haplotype -605G\143G\3836T was significantly associated with higher plasma urotensin level, plasma insulin level, insulin resistance and β-cell function. In non-diabetic subjects, insulin secretion normally increases as a compensatory adaptation under the condition of insulin resistance [43] . The mechanism whereby this haplotype in U-II can cause insulin resistance remains speculative at present.
However, it has been demonstrated that U-II can increase the releases of adrenocorticotropic hormone (ACTH) and epinephrine through sympathoadrenal and pituitary-adrenal pathways [42] . The increase in ACTH may then contribute to an increase in insulin secretion. 16 Moreover, insulin has vascular effects in addition to its metabolic effects; it induces endothelial-nitric-oxide-dependent vasodilatation as well as glucose uptake into peripheral tissues [4] . It is possible that U-II impairs both of these actions like endothelin-1 [46] .
In this study, we found that the U-II haplotype -605G/143G/3836T was associated with higher plasma U-II level. In fact, 3836C>T was responsible for the association. This Although U-II is a highly potent vasoconstrictor in vitro, its infusion in man does not produce such a response [1, 47] . We and others postulate that the net effect of U-II on vascular tone is determined by the balance between its direct vasoconstrictor effect and its indirect vasodilatory effect mediated by endothelium derived relaxing factors such as nitric oxide [6, 17, 23] . In diseases characterised by endothelial dysfunction, the vasoconstriction and the mitogenic effect on vascular smooth muscle may predominate. In this regard, we have observed that tumour necrosis factor-alpha (TNF-α) upregulates the expression of U-II and the UT receptor in endothelial cells in vitro [unpublished observations]. There is increased secretion of TNF-α and other inflammatory cytokines in the whole spectrum of cardiovascular disease and cardiovascular risk factors, including the metabolic syndrome [25, 44] . U-II may therefore have a role in the pathogenesis of cardiovascular diseases and complications.
Genetic association studies are prone to false positives when multiple SNPs are tested in large sample sizes. Therefore, we have focussed on haplotypes made up of common alleles and large effect sizes. The population in Hong Kong is 95% Chinese, so population stratification is unlikely to be serious. Nevertheless, our results need to be confirmed in further studies in a different setting and population.
In conclusion, our study showed that haplotypes and SNPs in the UTS2 and UTS2R genes in Hong Kong Chinese were associated with plasma U-II level, pancreatic β-cell function, insulin resistance and 2-hour plasma glucose although they were not associated with hypertension. These suggest that U-II and its receptor may play a role in the development of insulin resistance, hyperinsulinemia and impaired glucose tolerance, components of metabolic syndrome. Table 1 Baseline characteristics of the 530 subjects Table 2 Allelic frequencies of SNPs in normotensive and hypertensive subjects Table 3 Association between the SNPs and haplotypes of UTS2 gene and plasma urotensin II level Table 4 Effect of the SNPs, -605G>A, 143G>A and 3836C>T in UTS2 gene and the corresponding haplotypes on fasting plasma insulin, HOMA-IR and HOMA-β% Table 5 Effect of the SNPs, -11640G>A and -8515T>C in UTS2R gene and the cooresponding haplotypes on 2 hour plasma glucose level after oral glucose tolerance test and plasma cholesterol level 
